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Identification of commercially available antibodies that block 
ligand-binding by BMPR2 
Ruthann Gorrell & Jonathan W. Lowery, PhD 
Division of Biomedical Science, Marian University College of Osteopathic Medicine, Indianapolis, Indiana, USA 
Osteoporosis, a disease of low bone mineral density, affects 10 million Americans 
and is a significant health problem and a considerable socioeconomic burden. 
Current treatments for osteoporosis have significant limitations, necessitating 
identifying new treatment strategies via building a better understanding of the 
endogenous mechanisms regulating bone mass. Recent research demonstrated that 
removal of the BMP type 2 receptor, BMPR2, in skeletal progenitor cells of Bmpr2-
cKO mice leads to reduced age-related bone loss due to a sustained elevation in 
bone formation rate. The molecular mechanism underlying this phenotype is being 
pursued in other work. In the present study, we sought to advance the translational 
potential of the genetic model by identifying antibodies that neutralize the ligand-
binding function of the BMPR2 extracellular domain (BMPR2-ECD). Using a 
modified, cell-free immunoprecipitation assay quantified by ELISA, we examined the 
neutralizing ability of 3F6, which is a mouse monoclonal antibody raised against the 
ligand-binding region of BMPR2, and found a dose-dependent inhibition of BMPR2-
ECD ligand-binding. We then evaluated 1F12, which is another mouse monoclonal 
antibody raised against the ligand-binding region of BMPR2, and found that this 
antibody is also capable of neutralizing the ligand binding function of BMPR2-ECD. 
We extended the results by examining the ability of 3F6 to block endogenous 
BMPR2 function in the BMP-responsive HEK293T (human kidney embryonic 293 
translation) cell line. Consistent with the results of our cell-free system, pre-treatment 
of HEK293T cells with 3F6 leads to reduced sensitivity to in response to BMP 
pathway activation by BMP2. These results provide proof-of-concept data for future 
studies evaluating inhibition of BMPR2 function in vivo as a means to reduce age-
related bone loss. 
Figure. 1 High peak bone mass 
and reduced age-related decline in 
bone mass of female BMPR2 
mutant mice. AB: Trabecular 
volumetric bone mineral density 
(vBMD) quantified by micro-CT in 
tibiae of females control and BMPR2 
mutant mice at 55 weeks of age (A) 
and change between 15 and 55 
weeks of age (B).  
Central Research Question: 
 
Can ligand-binding ability of the 
BMPR2 extracellular domain 
(BMPR2-ECD) be blocked using 
commercially available antibodies? 
 
Acknowledgements: 
This work was performed in collaboration with: 
 Laura Schoerning  Jordan Newby Warren Lawless
 Aaron Hudnall Julia Hum, PhD 
 
Supported by a MU-COM Faculty Research Development award issued to JWL. 
Figure. 2 Antibodies 3F6 and 1F12 inhibit BMPR2-ECD ligand-binding in a 
modified, cell-free immunoprecipitation assay quantified by ELISA. A: α-
BMP2, bound to well, binds BMP2 (A1), so that quantitative ELISA showed dose-
dependent increases in absorbance (A2). B: Noggin bound BMP2 (B1), resulting 
in a dose-dependent decrease in signal (B2). C: BMPR2-ECD also bound BMP2 
(C1), resulting in a dose-dependent decrease in signal (C2). D: 3F6 blocked 
BMPR2-ECD (D1), resulting in a dose-dependent decrease in BMPR2-ECD 
activity (D2). E: Second lot of 3F6 verified previous findings (D1&2). F: 1F12 also 
bound BMPR2-ECD, resulting in a decrease in BMPR2-ECD activity. *indicates 
p<0.05 by unpaired t test versus control. 
Conclusions: 
Our results provide proof-of-concept data that BMPR2 function can be blocked using 
a neutralizing antibody approach. Specifically, the mouse monoclonal antibodies 3F6 
and 1F12 block BMPR2-ECD ligand-binding in a cell-free immunoprecipitation assay. 
3F6 was additionally shown to block BMP2-induced pathway activation in HEK293T 
cells. An incidental finding from our study is that BMPR2 is the major receptor for 
BMP2 in HEK293T cells. 
 
Current and Future Directions:  
1) Examination of 3F6 and 1F12 neutralizing activity of BMPR2 function in skeletal 
cells in vitro. 
2) Examination of systemic delivery of 3F6 and/or 1F12 in vivo as a means of 
regulating postnatal bone mass. 
Figure. 3 Antibody 3F6 
inhibits BMP2-induced 
pathway activation in 
HEK293T cells. HEK293T 
cells were treated with BMP2 
for four hours +/- thirty 
minute pre-treatment with 
3F6 or control ascites. A-B: 
BMP pathway activation 
level, indicated by 
phoshorylation of S1/5/8 
(pS1/5/8), is reduced in the 
presence of 3F6. C-D: 
Ascites control does not 
inhibit BMP2-induced 
pathway activation. Data are 
expressed as mean+/- SEM 
relative to BMP2 alone. * 
indicates p<0.05 by unpaired 
t test versus BMP2 alone. 
A: Validation of BMP2 ELISA B: Proof-of-principle of ligand-binding assay 
C: Standardization of ligand-binding by BMPR2-ECD D: Identification of BMPR2-ECD neutralization by 3F6 
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